Close Menu

NEW YORK – Revolution Medicines announced today that it has dosed the first patient in a Phase Ib clinical trial evaluating its investigational SHP2 inhibitor, RMC-4630, in combination with Amgen's KRAS G12C inhibitor AMG510.

The open-label, dose escalation and expansion study, sponsored and conducted by Amgen, is evaluating the combination in patients with advanced solid tumors characterized by KRAS G12C mutations. Revolution is supplying RMC-4630 for the trial, in which researchers will also track the safety, efficacy, and pharmacokinetics of the combination.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.